Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist
P. K. Um, M. Praharaj, K. A. Lombardo, T. Yoshida, A. Matoso, A. S. Baras, L. Zhao, G. Srikrishna, J. Huang, P. Prasad, M. Kates, D. McConkey, D. M. Pardoll, W. R. Bishai, T. J. Bivalacqua
This study evaluates a recombinant BCG strain that releases a STING agonist, showing improved antitumor efficacy in bladder cancer models compared to wild-type BCG.
bioRxiv · Dec 15, 2023 · PreprintCancer Biology